EP3212290A4 - Polypeptides de fusion de serpine et leurs procédés d'utilisation - Google Patents

Polypeptides de fusion de serpine et leurs procédés d'utilisation Download PDF

Info

Publication number
EP3212290A4
EP3212290A4 EP15854670.5A EP15854670A EP3212290A4 EP 3212290 A4 EP3212290 A4 EP 3212290A4 EP 15854670 A EP15854670 A EP 15854670A EP 3212290 A4 EP3212290 A4 EP 3212290A4
Authority
EP
European Patent Office
Prior art keywords
methods
fusion polypeptides
serpin fusion
serpin
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP15854670.5A
Other languages
German (de)
English (en)
Other versions
EP3212290A1 (fr
Inventor
Brendan P. Eckelman
John C. Timmer
Quinn Deveraux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inhibrx Inc
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/524,832 external-priority patent/US10400029B2/en
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of EP3212290A1 publication Critical patent/EP3212290A1/fr
Publication of EP3212290A4 publication Critical patent/EP3212290A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
EP15854670.5A 2014-10-27 2015-10-27 Polypeptides de fusion de serpine et leurs procédés d'utilisation Pending EP3212290A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/524,832 US10400029B2 (en) 2011-06-28 2014-10-27 Serpin fusion polypeptides and methods of use thereof
PCT/US2015/057533 WO2016069574A1 (fr) 2014-10-27 2015-10-27 Polypeptides de fusion de serpine et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
EP3212290A1 EP3212290A1 (fr) 2017-09-06
EP3212290A4 true EP3212290A4 (fr) 2019-01-23

Family

ID=55858243

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15854670.5A Pending EP3212290A4 (fr) 2014-10-27 2015-10-27 Polypeptides de fusion de serpine et leurs procédés d'utilisation

Country Status (14)

Country Link
EP (1) EP3212290A4 (fr)
JP (2) JP6737781B2 (fr)
KR (2) KR20170091096A (fr)
CN (2) CN107206257A (fr)
AU (2) AU2015339507B2 (fr)
BR (1) BR112017008525A2 (fr)
CA (1) CA2965151A1 (fr)
HK (1) HK1244460A1 (fr)
IL (2) IL251799B2 (fr)
MX (2) MX2017005467A (fr)
RU (1) RU2746550C2 (fr)
SG (2) SG11201703390SA (fr)
UA (1) UA127305C2 (fr)
WO (1) WO2016069574A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021008200A2 (pt) * 2018-10-29 2021-12-14 Spin Therapeutics Llc Composições e métodos para distúrbios de alfa-1-antitripsina
CN111989340A (zh) * 2018-11-18 2020-11-24 杭州博虎生物科技有限公司 一种重组人白细胞介素10融合蛋白及其应用
CN112315897A (zh) * 2020-11-04 2021-02-05 深圳前海鹰岗生物科技有限公司 一种抑制细胞炎症反应释放治疗痛风急性发作的聚合物微针及制备方法
WO2022133521A1 (fr) * 2020-12-21 2022-06-30 Macquarie University Traitement du glaucome
GB202102258D0 (en) 2021-02-17 2021-03-31 Arecor Ltd Novel composition
CA3205815A1 (fr) * 2021-03-03 2022-09-09 Alwin REITER Formulations de proteines de fusion ace2 fc
CN113325181A (zh) * 2021-04-25 2021-08-31 苏州市立医院(北区) 丝氨酸蛋白酶抑制剂在用于脓毒症早期预警的标志物中的应用
CN114874333A (zh) * 2021-10-18 2022-08-09 深圳科兴药业有限公司 一种生长激素融合蛋白及其应用
US20230364208A1 (en) 2022-05-16 2023-11-16 Inhibrx, Inc. Effective dosage of recombinant serpin-fc fusion protein for use in a method of treating aat deficiency in a subject

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004092219A2 (fr) * 2003-04-10 2004-10-28 Protein Design Labs, Inc Modification d'affinites de liaison pour fcrn ou de demi-vies de serum d'anticorps par mutagenese
WO2013003641A2 (fr) * 2011-06-28 2013-01-03 Inhibrx Llc Polypeptides de fusion à base de serpine et leurs procédés d'utilisation
US20130058919A1 (en) * 2002-03-01 2013-03-07 Xencor, Inc. Optimized Fc Variants and Methods for their Generation
WO2014001325A1 (fr) * 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Méthode de fabrication de conjugués d'anticorps à région fc comprenant au moins une entité de liaison qui se lie spécifiquement à une cible et leurs utilisations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537810A (ja) * 1999-03-01 2002-11-12 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトセルピンタンパク質
ZA200601420B (en) * 2003-07-18 2007-06-27 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
EP3192872A1 (fr) * 2003-08-26 2017-07-19 The Regents of the University of Colorado, a body corporate Inhibiteurs de l'activité de sérine protéase et leur utilisation dans les procédés et compositions pour le traitement des infections bactériennes
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
JP4652414B2 (ja) * 2004-11-12 2011-03-16 ゼンコー・インコーポレイテッド ＦｃＲｎとの変化した結合を有するＦｃ変異体
EP2083081A1 (fr) * 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions et procédés pour traiter une maladie avec des protéines de fusion FGFR
AU2006280004A1 (en) * 2005-08-12 2007-02-22 Schering Corporation MCP1 fusions
AU2009262199B2 (en) * 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
MX348166B (es) * 2008-12-19 2017-06-01 Macrogenics Inc Diacuerpos covalentes y sus usos.
KR101900280B1 (ko) * 2010-12-23 2018-11-08 얀센 바이오테크 인코포레이티드 활성 프로테아제-저항성 항체 Fc 돌연변이체
EP2691417B1 (fr) * 2011-03-29 2018-08-01 Roche Glycart AG Variants de fc d'anticorps
EP2726093A4 (fr) * 2011-06-28 2015-08-19 Inhibrx Llc Polypeptides de fusion de domaines d'une protéine acide du lactosérum et procédés d'utilisation de ceux-ci
EP2802653A4 (fr) * 2012-01-10 2015-09-02 Univ Colorado Regents Compositions de molécules de fusion de l'alpha-1 antitrypsine, procédés et utilisations associés
CN104582736A (zh) * 2012-06-21 2015-04-29 印第安纳大学研究及科技有限公司 Fc效应子功能改变的肠降血糖素受体配体多肽Fc区融合多肽和缀合物
PL2880170T3 (pl) * 2012-08-02 2017-02-28 F.Hoffmann-La Roche Ag SPOSÓB WYTWARZANIA ROZPUSZCZALNEGO FcR JAKO FUZJI Fc Z OBOJĘTNYM REGIONEM Fc IMMUNOGLOBULINY I JEGO ZASTOSOWANIA
US9758807B2 (en) * 2012-12-05 2017-09-12 SOLA Biosciences, LLC Protein expression enhancing polypeptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130058919A1 (en) * 2002-03-01 2013-03-07 Xencor, Inc. Optimized Fc Variants and Methods for their Generation
WO2004092219A2 (fr) * 2003-04-10 2004-10-28 Protein Design Labs, Inc Modification d'affinites de liaison pour fcrn ou de demi-vies de serum d'anticorps par mutagenese
WO2013003641A2 (fr) * 2011-06-28 2013-01-03 Inhibrx Llc Polypeptides de fusion à base de serpine et leurs procédés d'utilisation
WO2014001325A1 (fr) * 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Méthode de fabrication de conjugués d'anticorps à région fc comprenant au moins une entité de liaison qui se lie spécifiquement à une cible et leurs utilisations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2016069574A1 *

Also Published As

Publication number Publication date
SG11201703390SA (en) 2017-05-30
IL308589A (en) 2024-01-01
BR112017008525A2 (pt) 2018-01-30
JP6737781B2 (ja) 2020-08-12
CA2965151A1 (fr) 2016-05-06
SG10201903142RA (en) 2019-05-30
WO2016069574A1 (fr) 2016-05-06
AU2015339507A1 (en) 2017-05-11
AU2015339507B2 (en) 2021-07-01
JP2020180157A (ja) 2020-11-05
AU2021240153A1 (en) 2021-10-28
MX2017005467A (es) 2017-11-30
MX2021012047A (es) 2021-11-03
JP2017537888A (ja) 2017-12-21
IL251799B1 (en) 2023-12-01
UA127305C2 (uk) 2023-07-19
KR20170091096A (ko) 2017-08-08
IL251799B2 (en) 2024-04-01
RU2017118325A3 (fr) 2019-03-21
RU2746550C2 (ru) 2021-04-15
RU2017118325A (ru) 2018-11-29
KR20240005109A (ko) 2024-01-11
IL251799A0 (en) 2017-06-29
CN107206257A (zh) 2017-09-26
HK1244460A1 (zh) 2018-08-10
EP3212290A1 (fr) 2017-09-06
CN114316068A (zh) 2022-04-12

Similar Documents

Publication Publication Date Title
IL275307B (en) Syntac polypeptides and their uses
HRP20190028T1 (hr) Interleukin-2 fuzijski proteini i njihove primjene
EP3390624A4 (fr) Polypeptides de modification ciblée modifiés et leurs procédés d'utilisation
EP3148573A4 (fr) Protéines de fusion ox40l et leurs utilisations
EP3147298A4 (fr) Protéine de fusion pd-l1 et son utilisation
EP3154582A4 (fr) Glycoanticorps anti-thf-alpha et leurs utilisations
EP3455263A4 (fr) Polypeptides de fusion cd40l-fc et procédés d'utilisation associés
HK1244460A1 (zh) 絲氨酸融合多肽和其使用方法
EP3154972A4 (fr) Dérivés d'azamophinan et leur utilisation
EP3240576A4 (fr) Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
EP3349851A4 (fr) Polypeptides photosensibles et leurs procédés d'utilisation
HK1243443A1 (zh) C1酯酶抑制劑融合蛋白及其用途
EP3107569A4 (fr) Anticorps anti-acth et leur utilisation
EP3129094A4 (fr) Bougie et son procédé de fabrication et d'utilisation
EP3092248A4 (fr) Polypeptides de fusion et leurs méthodes d'utilisation
EP3407871A4 (fr) Polypeptides alk et leurs procédés d'utilisation
EP3199543A4 (fr) Nouveau peptide et utilisation associee
EP3193755A4 (fr) Systèmes de fusion et procédés d'assemblage et d'utilisation associés
GB201410031D0 (en) Polypeptides and uses thereof
EP3237452A4 (fr) Protéines de fusion et procédés associés
EP3322736A4 (fr) Polypeptides de fusion et leurs procédés d'utilisation
EP3325499A4 (fr) Nouveau peptide et utilisation associée
EP3209697A4 (fr) Protéines de liaison à fn14 et leurs utilisations
EP3204003A4 (fr) Sélénosucres et leurs utilisations thérapeutiques
EP3166406A4 (fr) Bioconjugués de chitosane-cytokine et procédés pour les utiliser

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170511

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1244460

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/24 20060101ALI20180808BHEP

Ipc: C07K 14/81 20060101ALI20180808BHEP

Ipc: C07K 16/00 20060101ALI20180808BHEP

Ipc: A61P 37/00 20060101AFI20180808BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20190104

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 37/00 20060101AFI20181220BHEP

Ipc: C07K 16/24 20060101ALI20181220BHEP

Ipc: C07K 16/00 20060101ALI20181220BHEP

Ipc: C07K 14/81 20060101ALI20181220BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20211104

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230523

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: INHIBRX, INC.